|
1
|
Baxter EJ, Scott LM, Campbell PJ, et al;
Cancer Genome Project. Acquired mutation of the tyrosine kinase
JAK2 in human myeloproliferative disorders. Lancet. 365:1054–1061.
2005.
|
|
2
|
Jelinek J, Oki Y, Gharibyan V, et al: JAK2
mutation 1849G>T is rare in acute leukemias but can be found in
CMML, Philadelphia chromosome-negative CML, and megakaryocytic
leukemia. Blood. 106:3370–3373. 2005.
|
|
3
|
Levine RL, Loriaux M, Huntly BJ, et al:
The JAK2V617F activating mutation occurs in chronic myelomonocytic
leukemia and acute myeloid leukemia, but not in acute lymphoblastic
leukemia or chronic lymphocytic leukemia. Blood. 106:3377–3379.
2005.
|
|
4
|
Wang YL, Lee JW, Kui JS, et al: Evaluation
of JAK2 in B and T cell neoplasms: identification of JAK2(V617F)
mutation of undetermined significance (JMUS) in the bone marrow of
three individuals. Acta Haematol. 118:209–214. 2007.
|
|
5
|
Zhao W, Gao R, Lee J, Xing S, et al:
Relevance of JAK2V617F positivity to hematological diseases -
survey of samples from a clinical genetics laboratory. J Hematol
Oncol. 4:42011.
|
|
6
|
Stijnis C, Kroes WG, Balkassmi S, et al:
No evidence for JAK2(V617F) mutation in monoclonal B cells in 2
patients with polycythaemia vera and concurrent monoclonal B cell
disorder. Acta Haematol. 128:183–186. 2012.
|
|
7
|
Eskazan AE, Salihoglu A, Diz-Kucukkaya R,
et al: Chronic lymphocytic leukemia developing in a patient with
Janus kinase 2 V617F mutation positive myeloproliferative neoplasm.
Ann Hematol. 91:305–306. 2012.
|
|
8
|
Kodali S, Chen C, Rathnasabapathy C and
Wang JC: JAK2 mutation in a patient with CLL with coexistent
myeloproliferative neoplasm (MPN). Leuk Res. 33:e236–e239.
2009.
|
|
9
|
Tabaczewski P, Nadesan S and Lim SH:
Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2
V671F positive essential thrombocythemia: a common defective stem
cell? Leuk Res. 33:854–855. 2009.
|
|
10
|
Laurenti L, Tarnani M, Nichele I, et al:
The coexistence of chronic lymphocytic leukemia and
myeloproliferative neoplasms: a retrospective multicentric GIMEMA
experience. Am J Hematol. 86:1007–1012. 2011.
|
|
11
|
Wei J, Wang C, Qin YW, et al: JAK2 V617F
positive essential thrombocythemia developing in a patient with
CD5− chronic lymphocytic leukemia. Chin Med J (Engl).
125:2076–2079. 2012.
|
|
12
|
Swierczek S, Nausova J, Jelinek J, et al:
Concomitant JAK2 V617F-positive polycythemia vera and B-cell
chronic lymphocytic leukemia in three patients originating from two
separate hematopoietic stem cells. Am J Hematol. 88:157–158.
2013.
|
|
13
|
Musolino C, Allegra A, Penna G, et al:
Absence of the V617F JAK2 mutation in the lymphoid compartment in a
patient with essential thrombocythemia and B-chronic lymphocytic
leukemia and in two relatives with lymphoproliferative disorders.
Acta Haematol. 122:46–49. 2009.
|
|
14
|
Henry L, Carillo S, Jourdan E, et al:
Association of essential thrombocythemia and chronic lymphocytic
leukemia: absence of the V617F JAK2 mutation in the lymphoid
compartment. Am J Hematol. 82:500–501. 2007.
|
|
15
|
Hussein K, Brakensiek K, Ballmaier M, et
al: B-CLL developing in a patient with PV is not affected by V617F
mutation of the Janus kinase 2. Eur J Haematol. 77:539–541.
2006.
|
|
16
|
Hallek M: Chronic lymphocytic leukemia:
2013 update on diagnosis, risk stratification and treatment. Am J
Hematol. 88:803–816. 2013.
|
|
17
|
Zehentner BK, Loken MR and Wells DA:
JAK2V617F mutation can occur exclusively in the erythroid lineage
and be absent in granulocytes and progenitor cells in classic
myeloproliferative disorders. Am J Hematol. 81:806–807. 2006.
|
|
18
|
Ishii T, Bruno E, Hoffman R and Xu M:
Involvement of various hematopoietic-cell lineages by the JAK2V617F
mutation in polycythemia vera. Blood. 108:3128–3134. 2006.
|
|
19
|
Larsen TS, Christensen JH, Hasselbalch HC
and Pallisgaard N: The JAK2 V617F mutation involves B- and
T-lymphocyte lineages in a subgroup of patients with
Philadelphia-chromosome negative chronic myeloproliferative
disorders. Br J Haematol. 136:745–751. 2007.
|
|
20
|
Delhommeau F, Dupont S, Tonetti C, et al:
Evidence that the JAK2 G1849T (V617F) mutation occurs in a
lymphomyeloid progenitor in polycythemia vera and idiopathic
myelofibrosis. Blood. 109:71–77. 2007.
|
|
21
|
Bogani C, Guglielmelli P, Antonioli E, et
al: B-, T-, and NK-cell lineage involvement in JAK2V617F-positive
patients with idiopathic myelofibrosis. Haematologica. 92:258–259.
2007.
|
|
22
|
Khwaja A: The role of Janus kinases in
haemopoiesis and haematological malignancy. Br J Haematol.
134:366–384. 2006.
|
|
23
|
Kaushansky K: On the molecular origins of
the chronic myeloproliferative disorders: it all makes sense.
Blood. 105:4187–4190. 2005.
|
|
24
|
James C, Ugo V, Le Couédic JP, et al: A
unique clonal JAK2 mutation leading to constitutive signaling
causes polycythaemia vera. Nature. 434:1144–1148. 2005.
|
|
25
|
dos Santos NR and Ghysdael J: A transgenic
mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia.
Leukemia. 20:182–185. 2006.
|
|
26
|
Adélaïde J, Pérot C, Gelsi-Boyer V, et al:
A t(8;9) translocation with PCM1-JAK2 fusion in a patient with
T-cell lymphoma. Leukemia. 20:536–537. 2006.
|
|
27
|
Zhang Q, Raghunath PN, Xue L, et al:
Multilevel dysregulation of STAT3 activation in anaplastic lymphoma
kinase-positive T/null-cell lymphoma. J Immunol. 168:466–474.
2002.
|
|
28
|
Melzner I, Bucur AJ, Brüderlein S, et al:
Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains
phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood.
105:2535–2542. 2005.
|
|
29
|
Sidon P, El Housni H, Dessars B and
Heimann P: The JAK2V617F mutation is detectable at very low level
in peripheral blood of healthy donors. Leukemia. 20:16222006.
|
|
30
|
Xu X, Zhang Q, Luo J, et al: JAK2(V617F):
Prevalence in a large Chinese hospital population. Blood.
109:339–342. 2007.
|
